Information Provided By:
Fly News Breaks for November 28, 2018
LOXO
Nov 28, 2018 | 07:41 EDT
Citi analyst Yigal Nochomovitz lowered his price target for Loxo Oncology to $201 from $213 while keeping a Buy rating on the shares. The analyst says that with the adult price-point of $32,800 for Vitrakvi appearing the highest announced-to-date for a targeted/precision cancer therapy, he removed his estimate for 5% year-over-year price increases.
News For LOXO From the Last 2 Days
There are no results for your query LOXO
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.